
    
      OUTLINE:

      INDUCTION: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1.
      Patients also receive rituximab or obinutuzumab IV on days 1, 8, and 15 of cycle 1 and on day
      1 of cycle 2. Cycles repeat every 3 weeks for 4 cycles in the absence of disease progression
      or unacceptable toxicity.

      EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30
      minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (35 cycles) in the absence of
      disease progression or unacceptable toxicity. Patients also receive obinutuzumab Iv on day 1
      of cycles 5, 9, 13, 17, 21, and 25 only.

      After completion of study treatment, patients are followed up for 90 days.
    
  